Cargando…

Tenascin-C: Exploitation and collateral damage in cancer management

Despite an increasing knowledge about the causes of cancer, this disease is difficult to cure and still causes far too high a death rate. Based on advances in our understanding of disease pathogenesis, novel treatment concepts, including targeting the tumor microenvironment, have been developed and...

Descripción completa

Detalles Bibliográficos
Autores principales: Spenlé, Caroline, Saupe, Falk, Midwood, Kim, Burckel, Hélène, Noel, Georges, Orend, Gertraud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422814/
https://www.ncbi.nlm.nih.gov/pubmed/25569113
http://dx.doi.org/10.1080/19336918.2014.1000074
_version_ 1782370113442283520
author Spenlé, Caroline
Saupe, Falk
Midwood, Kim
Burckel, Hélène
Noel, Georges
Orend, Gertraud
author_facet Spenlé, Caroline
Saupe, Falk
Midwood, Kim
Burckel, Hélène
Noel, Georges
Orend, Gertraud
author_sort Spenlé, Caroline
collection PubMed
description Despite an increasing knowledge about the causes of cancer, this disease is difficult to cure and still causes far too high a death rate. Based on advances in our understanding of disease pathogenesis, novel treatment concepts, including targeting the tumor microenvironment, have been developed and are being combined with established treatment regimens such as surgical removal and radiotherapy. Yet it is obvious that we need additional strategies to prevent tumor relapse and metastasis. Given its exceptional high expression in most cancers with low abundance in normal tissues, tenascin-C appears an ideal candidate for tumor treatment. Here, we will summarize the current applications of targeting tenascin-C as a treatment for different tumors, and highlight the potential of this therapeutic approach.
format Online
Article
Text
id pubmed-4422814
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-44228142016-01-08 Tenascin-C: Exploitation and collateral damage in cancer management Spenlé, Caroline Saupe, Falk Midwood, Kim Burckel, Hélène Noel, Georges Orend, Gertraud Cell Adh Migr Reviews Despite an increasing knowledge about the causes of cancer, this disease is difficult to cure and still causes far too high a death rate. Based on advances in our understanding of disease pathogenesis, novel treatment concepts, including targeting the tumor microenvironment, have been developed and are being combined with established treatment regimens such as surgical removal and radiotherapy. Yet it is obvious that we need additional strategies to prevent tumor relapse and metastasis. Given its exceptional high expression in most cancers with low abundance in normal tissues, tenascin-C appears an ideal candidate for tumor treatment. Here, we will summarize the current applications of targeting tenascin-C as a treatment for different tumors, and highlight the potential of this therapeutic approach. Taylor & Francis 2015-01-08 /pmc/articles/PMC4422814/ /pubmed/25569113 http://dx.doi.org/10.1080/19336918.2014.1000074 Text en © 2015 The Author(s). Published with License by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Reviews
Spenlé, Caroline
Saupe, Falk
Midwood, Kim
Burckel, Hélène
Noel, Georges
Orend, Gertraud
Tenascin-C: Exploitation and collateral damage in cancer management
title Tenascin-C: Exploitation and collateral damage in cancer management
title_full Tenascin-C: Exploitation and collateral damage in cancer management
title_fullStr Tenascin-C: Exploitation and collateral damage in cancer management
title_full_unstemmed Tenascin-C: Exploitation and collateral damage in cancer management
title_short Tenascin-C: Exploitation and collateral damage in cancer management
title_sort tenascin-c: exploitation and collateral damage in cancer management
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422814/
https://www.ncbi.nlm.nih.gov/pubmed/25569113
http://dx.doi.org/10.1080/19336918.2014.1000074
work_keys_str_mv AT spenlecaroline tenascincexploitationandcollateraldamageincancermanagement
AT saupefalk tenascincexploitationandcollateraldamageincancermanagement
AT midwoodkim tenascincexploitationandcollateraldamageincancermanagement
AT burckelhelene tenascincexploitationandcollateraldamageincancermanagement
AT noelgeorges tenascincexploitationandcollateraldamageincancermanagement
AT orendgertraud tenascincexploitationandcollateraldamageincancermanagement